<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706654</url>
  </required_header>
  <id_info>
    <org_study_id>31-07-247</org_study_id>
    <nct_id>NCT00706654</nct_id>
  </id_info>
  <brief_title>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</brief_title>
  <acronym>ASPIRE</acronym>
  <official_title>A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an
      intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients
      with schizophrenia

      The trial is designed into three treatment phases. Phase 1 is designed to allow for a subject
      to be converted from the current anti-psychotic treatment to oral non-generic aripiprazole
      monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2 the subject will be
      stabilized on oral non-generic aripiprazole monotherapy. Once the subject is stabilized in
      Phase 2 (oral stabilization phase from minimum 8 weeks to maximum 28 weeks), they are
      eligible to be randomized into the double-blind IM depot maintenance phase, Phase 3. During
      Phase 3, the subject will be assessed for exacerbation of psychotic symptoms and impending
      relapse for up to 38 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, active-controlled study consisting of a screening
      phase and 3 treatment phases. Eligibility will be determined during a screening phase of 2 to
      42 days. Subjects currently receiving oral treatment with an anti-psychotic other than
      non-generic aripiprazole will enter Phase 1, and subjects with a lapse in aripiprazole or
      other anti-psychotic treatment at the time of study entry (&quot;lapse&quot; defined as &gt; 3 consecutive
      days without medication) will enter directly into Phase 2.

      During Phase 1 (oral conversion), subjects will be cross-titrated during weekly visits from
      other anti-psychotics to oral non-generic aripiprazole monotherapy over a minimum of 4 weeks
      and a maximum of 6 weeks. During Phase 2 (that will be a minimum of 8 weeks and a maximum of
      28 weeks in duration), subjects will be assessed bi-weekly and stabilized on an oral dose of
      aripiprazole ranging from 10 mg to 30 mg daily. After stability criteria are met at Phase 2,
      subjects are eligible to be randomized into the double-blind IM depot maintenance phase,
      Phase 3. Subjects will be randomized with a 2:2:1 (aripiprazole IM depot 300-400 mg monthly,
      oral aripiprazole 10-30 mg daily, aripiprazole IM depot 25-50 mg monthly). During Phase 3
      subjects will be assessed for impending relapse/exacerbation of psychotic symptoms. If a
      subject is identified with impending relapse/exacerbation of psychotic symptoms, they will be
      withdrawn from the trial and given the opportunity to enroll into an open-label aripiprazole
      IM depot trial, 31-08-248 (NCT00731549). Alternatively, any subject that discontinues in
      Phase 3 (up to and including Week 38) will have the option to enroll into an open-label
      aripiprazole IM depot trial, 31-08-248 (NCT00731549).

      The enrollment figure includes re-screened patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt; 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score &gt; 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Exacerbation of Psychotic Symptoms/Impending Relapse</measure>
    <time_frame>Baseline to the end of the study (Week 38)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders up to Week 38</measure>
    <time_frame>Baseline to the end of the study (Week 38)</time_frame>
    <description>A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Remission</measure>
    <time_frame>Baseline to the end of the study (Week 38)</time_frame>
    <description>A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">937</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Aripiprazole depot 300 or 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole 10-30 mg orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole depot 25 or 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole depot 300 or 400 mg</intervention_name>
    <description>Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.</description>
    <arm_group_label>Aripiprazole depot 300 or 400 mg</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole 10-30 mg orally</intervention_name>
    <description>Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.</description>
    <arm_group_label>Aripiprazole 10-30 mg orally</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole depot 25 or 50 mg</intervention_name>
    <description>Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.</description>
    <arm_group_label>Aripiprazole depot 25 or 50 mg</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo depot</intervention_name>
    <description>Placebo depot was supplied in lyophilized vials.</description>
    <arm_group_label>Aripiprazole 10-30 mg orally</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Placebo tablets were identical in appearance to the aripiprazole tablets.</description>
    <arm_group_label>Aripiprazole depot 300 or 400 mg</arm_group_label>
    <arm_group_label>Aripiprazole depot 25 or 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are able to provide written informed consent and/or consent obtained from
             a legally acceptable representative (as required by Institutional Review
             Board/Independent Ethics Committee [IRB/IEC]), prior to the initiation of any
             protocol-required procedures.

          -  Male and female subjects 18 to 60 years of age, inclusive, at time of informed
             consent.

          -  Subjects with a current diagnosis of schizophrenia as defined by Diagnostic and
             Statistical Manual of Mental Disorders, version 4, Text Revision (DSM-IV-TR) criteria
             and a history of the illness for at least 3 years prior to screening.

          -  Subjects who, in the investigator's judgment, require chronic treatment with an
             anti-psychotic medication.

          -  Subjects able to understand the nature of the study and follow protocol requirements,
             including the prescribed dosage regimens, tablet ingestion, IM depot injection,
             discontinuation of prohibited concomitant medications, who can read and understand the
             written word in order to complete patient-reported outcome measures, and who can be
             reliably rated on assessment scales.

        Exclusion Criteria:

          -  Subjects with a current DSM-IV-TR diagnosis other than schizophrenia, including
             schizoaffective disorder, major depressive disorder, bipolar disorder, delirium,
             dementia, amnestic, or other cognitive disorders. Also, subjects with borderline,
             paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.

          -  Subjects with schizophrenia that are considered resistant/refractory to antipsychotic
             treatment by history or response only to clozapine.

          -  Subjects with a significant risk of violent behavior or a significant risk of
             committing suicide based on history or investigator's judgment.

          -  Subjects who currently meet DSM-IV-TR criteria for substance dependence; including
             alcohol and benzodiazepines, but excluding caffeine and nicotine, or 2 positive drug
             screens for cocaine.

          -  Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment
             with aripiprazole or other quinolinones, or hypersensitivity to anti-psychotic agents,
             including aripiprazole.

          -  Subjects with a history of neuroleptic malignant syndrome or clinically significant
             tardive dyskinesia at screening.

          -  Subjects with uncontrolled thyroid function abnormalities.

          -  Subjects with a history of seizures, neuroleptic malignant syndrome, clinically
             significant tardive dyskinesia, or other medical condition that would expose the
             subject to undue risk or interfere with study assessments.

          -  Subjects who are involuntarily incarcerated.

          -  Subjects who have undergone electroconvulsive therapy within 180 days of entry into
             Phase 2.

          -  Subjects who have used an investigational agent within 30 days of screening; and prior
             participation in a clinical study with aripiprazole IM depot.

          -  Subjects with clinically significant abnormalities in laboratory test results, vital
             signs, or ECG results.

          -  Subjects hospitalized for more than 30 days in the 90 days prior to Phase 1 (or Phase
             2 for subjects bypassing Phase 1).

          -  Subjects requiring more than 1 benzodiazepine beyond screening (eg, lorazepam and
             oxazepam).

          -  Subjects who fail to wash-out from prohibited concomitant medications, including the
             use of CYP2D6 or CYP3A4 inhibitors or CYP3A4 inducers, antipsychotics, antidepressants
             (including monoamine oxidase inhibitors [MAOI]), and mood stabilizers, during
             screening and Phase 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Sanchez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21286</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Carolina</city>
        <state>North Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garfield Heights</city>
        <state>Ohio</state>
        <zip>44125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37614-1707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brugge</city>
        <zip>8200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bourgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pazardjik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>7510041</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>8053095</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>8330838</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <zip>8900085</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temuco</city>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valdivia</city>
        <zip>5090145</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <zip>10 090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jamejala</city>
        <state>Viljandi County</state>
        <zip>71024</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meegomäe</city>
        <zip>65526</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <zip>10613</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bully Les Mines</city>
        <zip>62160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elancourt</city>
        <zip>78990</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35703</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cegléd</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Győőor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belchatow</city>
        <zip>97-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-096</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Choroszcz</city>
        <zip>16-070</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leszno</city>
        <zip>64-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pruszków</city>
        <zip>05-802</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sosnowiec</city>
        <zip>41-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-227</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muang</city>
        <state>Chiangmai</state>
        <zip>50100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muang</city>
        <state>Chiangmai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <results_first_submitted>March 29, 2013</results_first_submitted>
  <results_first_submitted_qc>July 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 14, 2013</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aripiprazole</keyword>
  <keyword>Intramuscular (IM) depot</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 3 phases in this study. In phases 1 and 2 (Conversion Phase and Oral Stabilization Phase), there was 1 reporting group. In phase 3 (Depot Maintenance Phase), there were 3 reporting groups. All Outcome Measures were assessed in the Depot Maintenance Phase of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>During the Conversion Phase, patients were cross-titrated from other antipsychotics to oral non-generic aripiprazole monotherapy and during the Oral Stabilization Phase, patients were stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Aripiprazole Depot 300 or 400 mg</title>
          <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Aripiprazole 10-30 mg Orally</title>
          <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Aripiprazole Depot 25 or 50 mg</title>
          <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Conversion Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="709"/>
                <participants group_id="P2" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P4" count="0">There were no patients in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="614"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Discontinued Trial</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Oral Stabilization Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="842">228 of the 842 patients who started this phase enrolled directly into this phase of the study.</participants>
                <participants group_id="P2" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="0">There were no patients in this reporting group in this phase of the study.</participants>
                <participants group_id="P4" count="0">There were no patients in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="662"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Discontinue Trial</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Depot Maintenance Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients were randomized into the 3 aripiprazole treatment groups in this phase of the study.</participants>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="178"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event without Impending Relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Impending Relapse with Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Impending Relapse without Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline measures are based on the participants from the Depot Maintenance Phase.</population>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Aripiprazole 10-30 mg Orally - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="265"/>
            <count group_id="B2" value="266"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="662"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="10.4"/>
                    <measurement group_id="B2" value="41.2" spread="10.8"/>
                    <measurement group_id="B3" value="40.2" spread="9.6"/>
                    <measurement group_id="B4" value="40.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26</title>
        <description>A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt; 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score &gt; 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.</description>
        <time_frame>Baseline to Week 26</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 10-30 mg Orally - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26</title>
          <description>A patient had exacerbation of psychotic symptoms/impending relapse if they met any of the following 4 criteria. 1) Clinical Global Impression of Improvement score ≥ 5 and either an increase on any of the following Positive and Negative Syndrome Scale (PANSS) items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) to a score &gt; 4 with an increase of ≥ 2 on that item since randomization or an increase on any of the same PANSS items to a score &gt; 4 and an increase of ≥ 4 on the same combined PANSS items since randomization, 2) Hospitalization due to worsening of psychotic symptoms, 3) Clinical Global Impression of Severity of Suicide (CGI-SS) score of 4 or 5 on Part 1 and/or 6 or 7 on Part 2, or 4) Violent behavior resulting in clinically significant self-injury, injury to another person, or property damage.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" spread="1.62"/>
                    <measurement group_id="O2" value="7.76" spread="1.72"/>
                    <measurement group_id="O3" value="21.80" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample sizes were estimated to achieve 93% power for the primary non-inferiority 2-sided comparison at 0.05 significance using large sample normal approximations for the distribution of the difference in binomial proportions. The assumed proportion of impending relapse at or before Week 26 for the oral aripiprazole 10-30 mg arm was 18% and the predefined non-inferiority margin was 11.5%. The sample size was projected to be 260 each for the IM depot 300 or 400 mg and oral 10-30 mg arms.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The test of non-inferiority of was performed using a 95% confidence interval (CI, 2-sided) for the difference in the estimated percentage of patients meeting exacerbation of psychotic symptoms/impending relapse criteria by the end of Week 26. Non-inferiority was considered confirmed if the upper bound of the 2-sided 95% CI was below the predefined margin, 11.5%.</non_inferiority_desc>
            <p_value>0.7871</p_value>
            <method>z-statistics</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.26</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
            <estimate_desc>The 95% CI of the difference in proportions of subjects with impending relapse events between aripiprazole IM depot 300 or 400 mg mg and oral aripiprazole were provided using the pooled SE with assumption of normality of the estimated difference.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the superiority comparison (assay sensitivity analysis) of IM depot 300 or 400 mg to IM depot 25 or 50 mg, on a 2:1 randomization, sample sizes of 260 and 130, respectively, were calculated to provide about 95% power at the 0.05 significance level (2-sided). A superiority margin of 17% was assumed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Once non-inferiority was declared, superiority of depot 300/400 mg over depot 25/50 mg was tested by the difference between the proportion of subjects experiencing impending relapse by the end of Week 26 (2-sided 0.05 significance level z-statistic).</p_value_desc>
            <method>z-statistics</method>
            <method_desc>The same method was used to compare IM depot 300 or 400 mg with IM depot 25 or 50 mg in the estimated proportion of subjects with impending relapse.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.09</ci_lower_limit>
            <ci_upper_limit>-6.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Exacerbation of Psychotic Symptoms/Impending Relapse</title>
        <time_frame>Baseline to the end of the study (Week 38)</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 10-30 mg Orally - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Exacerbation of Psychotic Symptoms/Impending Relapse</title>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="266"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Due to the low (&lt; 50%) percentage of relapses, median time to exacerbation could not be estimated.</measurement>
                    <measurement group_id="O2" value="NA">Due to the low (&lt; 50%) percentage of relapses, median time to exacerbation could not be estimated.</measurement>
                    <measurement group_id="O3" value="NA">Due to the low (&lt; 50%) percentage of relapses, median time to exacerbation could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders up to Week 38</title>
        <description>A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.</description>
        <time_frame>Baseline to the end of the study (Week 38)</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 10-30 mg Orally - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders up to Week 38</title>
          <description>A patient was considered to be a responder if all of the following criteria were met. 1) Outpatient status, 2) PANSS total score ≤ 80, 3) Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): Conceptual disorganization, suspiciousness, hallucinatory behavior, unusual thought content, and 4) Clinical Global Impression of Severity of Illness (CGI-S) ≤ 4 (moderately ill) and 5) CGI-SS ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8"/>
                    <measurement group_id="O2" value="89.4"/>
                    <measurement group_id="O3" value="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8750</p_value>
            <method>z-statistics</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>z-statistics</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Remission</title>
        <description>A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).</description>
        <time_frame>Baseline to the end of the study (Week 38)</time_frame>
        <population>Intent-to-treat population: All randomized patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aripiprazole 10-30 mg Orally - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase</title>
            <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Remission</title>
          <description>A patient was considered to have achieved remission if they had a score of ≤ 3 on each of the following PANSS items, maintained for a period of 6 months: Delusions (P1), unusual thought content (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (N1), social withdrawal (N4), and lack of spontaneity (N6).</description>
          <population>Intent-to-treat population: All randomized patients.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="53.2"/>
                    <measurement group_id="O3" value="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3700</p_value>
            <method>z-statistics</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1097</p_value>
            <method>z-statistics</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time of the signing of informed consent until the end of the study.</time_frame>
      <desc>Safety population: All randomized subjects who received at least 1 dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients - Conversion Phase</title>
          <description>During the Conversion Phase, patients were cross-titrated from other antipsychotics to oral non-generic aripiprazole monotherapy.</description>
        </group>
        <group group_id="E2">
          <title>All Patients - Oral Stabilization Phase</title>
          <description>During the Oral Stabilization Phase, patients were stabilized on an oral dose of aripiprazole ranging from 10 mg to 30 mg daily.</description>
        </group>
        <group group_id="E3">
          <title>Aripiprazole Depot 300 or 400 mg - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Aripiprazole 10-30 mg Orally - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 10-30 mg orally daily for 38 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Aripiprazole Depot 25 or 50 mg - Depot Maintenance Phase</title>
          <description>Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Psychotic behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="161" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="142" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="74" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="709"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="842"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="265"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="266"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Affairs</name_or_title>
      <organization>Otsuka Pharmaceutical Development and Commercialization</organization>
      <phone>800 562-3974</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

